Lexeo Therapeutics publishes presentation on interim LX2020 trial data in PKP2 cardiomyopathy
LXEO•Lexeo Therapeutics published interim Phase 1/2 HEROIC-PKP2 trial data: seven high-dose participants showed an 80% mean reduction in NSVT burden and a 44% reduction in premature ventricular contraction burden. The FDA is open to guideline-defined NSVT as a primary surrogate endpoint for potential accelerated approval, with pivotal study design finalization expected in the first half of 2027.
1. Interim trial results
In seven high-dose participants, NSVT burden fell by a mean 80% and premature ventricular contraction burden fell 44%. LX2020 was generally well tolerated across 10 participants; one previously disclosed Grade 3 serious adverse event involved sustained ventricular tachycardia.
2. Potential approval pathway
The FDA is open to guideline-defined NSVT as a primary surrogate endpoint supporting potential accelerated approval of LX2020. Lexeo expects to finalize pivotal study design in the first half of 2027 and initiate the trial under the accelerated approval pathway in the second half.




